Contrasting Pulmatrix (NASDAQ:PULM) and Swedish Orphan Biovitrum (OTCMKTS:BIOVF)

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) and Pulmatrix (NASDAQ:PULM) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership.

Valuation and Earnings

This table compares Swedish Orphan Biovitrum and Pulmatrix”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Swedish Orphan Biovitrum	$2.89 billion	5.92	$48.85 million	$0.30	160.00
Pulmatrix	N/A	N/A	-$5.16 million	($1.23)	-1.36

Swedish Orphan Biovitrum has higher revenue and earnings than Pulmatrix. Pulmatrix is trading at a lower price-to-earnings ratio than Swedish Orphan Biovitrum, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Swedish Orphan Biovitrum and Pulmatrix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Swedish Orphan Biovitrum	0	3	4	0	2.57
Pulmatrix	1	0	0	0	1.00

Institutional and Insider Ownership

11.8% of Pulmatrix shares are held by institutional investors. 0.6% of Pulmatrix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Swedish Orphan Biovitrum and Pulmatrix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Swedish Orphan Biovitrum	3.37%	16.66%	8.96%
Pulmatrix	N/A	-107.84%	-91.58%

Volatility and Risk

Swedish Orphan Biovitrum has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Pulmatrix has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.

Summary

Swedish Orphan Biovitrum beats Pulmatrix on 9 of the 12 factors compared between the two stocks.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

About Pulmatrix

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.